Alpelisib in Treating Participants With Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer

Conditions:   CDKN2A-p16 Positive;   Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma;   Stage I Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7;   Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7;   Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7
Interventions:   Drug: Alpelisib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacodynamic Study;   Procedure: Therapeutic Conventional Surgery
Sponsors:   University of Arizona;   National Cancer Institute (NCI)
Not yet recruiting

https://ift.tt/2mJ1HUf